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Abstract
Background: In high-income countries, the incidence of severe postpartum hemorrhage (PPH) has increased. This has
important public health relevance because severe PPH is a leading cause of major maternal morbidity. However, few
studies have identified risk factors for severe PPH within a contemporary obstetric cohort.
Methods: We performed a case-control study to identify risk factors for severe PPH among a cohort of women who
delivered at one of three hospitals in Norway between 2008 and 2011. A case (severe PPH) was classified by an estimated
blood loss ≥1500 mL or the need for blood transfusion for excessive postpartum bleeding. Using logistic regression, we
applied a pragmatic strategy to identify independent risk factors for severe PPH.
Results: Among a total of 43,105 deliveries occurring between 2008 and 2011, we identified 1064 cases and 2059
random controls. The frequency of severe PPH was 2.5% (95% confidence interval (CI): 2.32–2.62). The most common
etiologies for severe PPH were uterine atony (60%) and placental complications (36%). The strongest risk
factors were a history of severe PPH (adjusted OR (aOR) = 8.97, 95% CI: 5.25–15.33), anticoagulant medication
(aOR = 4.79, 95% CI: 2.72–8.41), anemia at booking (aOR = 4.27, 95% CI: 2.79–6.54), severe pre-eclampsia or
HELLP syndrome (aOR = 3.03, 95% CI: 1.74–5.27), uterine fibromas (aOR = 2.71, 95% CI: 1.69–4.35), multiple pregnancy
(aOR = 2.11, 95% CI: 1.39–3.22) and assisted reproductive technologies (aOR = 1.88, 95% CI: 1.33–2.65).
Conclusions: Based on our findings, women with a history of severe PPH are at highest risk of severe PPH. As well as
other established clinical risk factors for PPH, a history of severe PPH should be included as a risk factor in
the development and validation of prediction models for PPH.
Keywords: Postpartum hemorrhage, Case-control study, Predictors, Risk factors, Obstetric interventions, High-risk,
Prediction, Prevention
Background
Severe postpartum hemorrhage (PPH) is the largest con-
tributor to maternal morbidity worldwide, accounting
for 50–75% of all such cases [1–4]. Consequently, PPH
has received increasing attention as a quality indicator
for obstetric care. Furthermore, evidence exists that the
incidence of PPH is increasing in high-income countries
[5–12]. An increase in the prevalence of known maternal
and obstetric risk factors for PPH could play a role, but
the supporting evidence from the published studies is
limited. For example, in a Canadian study [7], induction
of labor, augmentation of labor, and cesarean section
partially explained the increasing rate of PPH. These
findings may indicate that women undergoing these
interventions need closer monitoring for severe PPH in
the early postpartum period.
Several risk factors for PPH are known, such as
multiple pregnancy, operative delivery and chorionam-
nionitis, however PPH may occur among patients with
no known risk factors [13, 14]. Our ability to reduce the
risk of PPH depends on ongoing investigations of previ-
ously unaccounted for causes and risk factors.
The primary aim of the study was to evaluate risk
factors for severe PPH, taking into consideration pre-
pregnancy, antenatal and intrapartum variables.
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Methods
The source population was defined as pregnant women
living in the metropolitan area of the Oslo and Buskerud
municipality who were admitted to two university
hospitals in Oslo (Ullevaal or Rikshospitalet) or Dram-
men Hospital for delivery between January 1, 2008 and
December 31, 2011. From this source population, we
performed a retrospective case-control study. We identi-
fied 1064 cases of severe PPH through birth suite
records and hospital databases. Severe PPH was defined
as blood loss ≥1500 mL or the need for blood transfu-
sion for excessive bleeding at the time of delivery. Blood
transfusion for excessive bleeding was defined as a blood
transfusion given for a likely PPH ≥1500 mL due to
clinical symptoms and signs of anemia or hemodynamic
decompensation after delivery. We excluded women
who received a blood transfusion because of postpartum
anemia, without evidence of excessive hemorrhage. The
attending physician or midwife estimated the blood loss
visually in all three hospitals. Controls were a random
sample of all deliveries without severe PPH from the
same source population and period of time as the cases,
comprising a total of 2059 deliveries. We selected
random controls after removing the cases of severe PPH
from the total number of deliveries at the three
hospitals. Weighting was done according to the total
number of deliveries in each hospital during the study
period, resulting in control fractions from Rikshospitalet,
Ullevaal, and Drammen of 21%, 62%, and 17%, respect-
ively. Considering two controls per case, we estimated
the number of controls needed from each hospital
according to the number of delivering women in each
hospital compared to the total number. This rendered
sampling fractions at Rikshospitalet, Ullevaal, and
Drammen of 4.8%, 5.2%, and 4.7%, respectively. The ran-
dom sample was generated in STATA version 11.0 (Stata
Corp LP, College Station, TX, USA).
Registration of patient data was based on information
from 1) the hospitals’ medical records; 2) maternity
databases (Obstetrix® from Siemens AG, Oslo, Norway
and Partus® from Clinsoft, Oslo, Norway), and 3) birth
suite records containing labor and delivery outcomes on
all deliveries, including the volume of blood loss during
delivery. If a woman had more than one delivery, the
second and subsequent pregnancies were excluded to
limit repeated correlated measurements.
In this study, we distinguished between causes of and
risk factors for PPH; no direct causes were included in
the risk factor analyses. Causes of severe PPH were
classified as Tone (uterine atony, uterine inversion and
abruption of the placenta), Tissue (retained placenta and
retained parts of placenta, and abnormal placentation),
Trauma (uterine rupture, birth canal trauma, and
surgical trauma), and Thrombin (coagulation disorders).
We registered up to two causes for each case if both
were considered to be main causes, except in cases
labeled as atony due to retained placenta which were re-
ported as a retained placenta. A retained placenta neces-
sitating a manual or operative delivery of the placenta
was classified as a retained placenta. Cases with retained
placental tissues diagnosed in the operating theatre or
by ultrasound and needing surgical or manual removal,
were classified as retained placental tissue. Abnormal
placentation was defined as placenta accreta, increta or
percreta. We identified cases caused by abnormal
placentation post-delivery by reviewing medical records
and pathology reports.
Based on literature review, we selected potential risk
factors for consideration in our analyses. Pre-pregnancy
factors included marital status, ethnicity, uterine anom-
alies (septated uterus, uni- or bicornuate uterus, uterus
didelphys), previous uterine surgery (myomectomy and
septal removals), previous cesarean section, previous
severe PPH (≥1500 mL), and uterine fibromas. Current
pregnancy conditions included maternal age, ethnicity
(country of origin), pre-pregnancy body mass index
(BMI), anemia in start of pregnancy (hemoglobin
≤9 g/dL), assisted reproductive technology (in vitro
fertilization [IVF] or intra-cytoplasmic sperm injection
[ICSI]), multiple pregnancy, gestational diabetes (insulin
treated or diet regulated), use of anticoagulant medica-
tions such as low molecular weight heparin (LMWH) in
pregnancy, polyhydramnios, severe preeclampsia or
HELLP-syndrome, and premature rupture of membranes
(PROM). Intrapartum factors included maternal fever
(>38 °C) during delivery, mode of delivery, induction of
labor, labor augmentation with oxytocin, and infant birth
weight. Maternal age, BMI, and infant birth weight were
considered as continuous variables for inclusion in the
final model and categorical variables for descriptive
purposes. Age was divided into 5-year groups, using
20–24 years as the reference group. BMI was categorized
using the World Health Organization (WHO)’s classifica-
tion, with a BMI of 18.5-24.9 kg/m2 as the reference.
Infant birth weight was dichotomized into ≥4500 g or
<4500 g, according to the definition of fetal macrosomia
[15]. Furthermore, we used WHO’s world regions to
classify ethnic origin [16].
The data were entered into a database built in EpiData
Version 3.1. (EpiData Association, Odense, Denmark).
The medical records were re-examined if we observed
data outliers or categorization errors for independent
and dependent variables. All medical records were
reviewed by two investigators (LTN and SP).
For our sample size estimation, we considered mater-
nal age and induction of labor as potential risk factors
for severe PPH. For both sample size estimates, we
considered a type 1 error of 5%, a power of 80%, and a
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case:control ratio of 1:2. Regarding maternal age, in
Oslo, approximately 18% of parturients are 35 years or
older [17]. We hypothesized that women in this age
group had a 1.4-fold increased risk of severe PPH com-
pared to younger women [1, 18]. With a minimum
detectable odds ratio (OR) = 1.4, we would need at least
656 cases and 1312 controls for a total of 1968 patients.
Regarding induction of labor, in Norway, the frequency
of labors induced with oxytocin is 3.4% according to
figures from The Medical Birth Registry of Norway [17].
In a population-based study from Norway examining
risk factors for severe PPH, the total rate of induction of
labor was 10.8% [18]. We estimated that the frequency
of induction of labor would be around the mean of these
rates. Assuming a 1.6-fold increased risk of severe PPH
in induced labor [1, 18], we would need at least 698
cases and 1396 controls, totally 2094 patients, when
considering a minimum detectable OR = 1.6. Thus, for
this case–control study, we decided to include at least
2400 deliveries (800 cases and 1600 controls).
We analyzed the data according to a pragmatic strategy
[19], which means priority was not given to a specific etio-
logical hypothesis. Univariable analysis was done to assess
candidate variables as risk factors for severe PPH, and the
associations between potential risk factors and severe PPH
was quantified by the OR and 95% confidence interval (CI).
The multivariable analysis was preceded by estimation of
collinearity between risk factors. When collinearity existed
between two variables, we omitted the one with least
clinical relevance. Finally, multivariable logistic regression
with manual backward elimination was used to identify in-
dependent risk factors for severe PPH [20]. Our criteria for
sequential elimination of candidate risk factors were the
variables’ strength and significance on the association with
severe PPH, and optimal calibration and discrimination of
the model. The continuous variables of maternal age, BMI,
and birth weight were introduced into the model in its
logged form as they were linearly associated with the out-
come. However, birth weight is presented dichotomized in
Table 3 as this was judged clinically more interesting.
Because we were applying a pragmatic strategy, the pre-
dictive accuracy of the model was evaluated by calibration
and discrimination [21]. Calibration, which measures the
ability of the model to assign the appropriate risk, was
evaluated by the Hosmer and Lemeshow (H-L) goodness-
of-fit test. A statistically non-significant H-L result (P >
0.05) suggests that the model predicts accurately on
average. Discrimination, which measures the model’s abil-
ity to differentiate between individuals with and without
severe PPH, was evaluated by analysis of the area under
the receiver operating characteristic (ROC) curve. If the
area under the curve is greater than 0.7, it can be con-
cluded that the model has an acceptable discriminatory
capability. All statistical analysis was performed using
STATA version 11.0 (Stata Corp LP, College Station, TX,
USA). We used Strengthening the Reporting of Observa-
tional Studies in Epidemiology (STROBE) guidelines in
reporting our case–control study [22].
Results
From the source population of 43,105 deliveries, we
identified 1064 women with a recorded PPH of
≥1500 mL or blood transfusion, giving a frequency of
2.5% (95% CI: 2.32–2.62). The identified causes of severe
PPH are listed in Table 1. The most common cause was
uterine atony (60.4%), while we identified retained pla-
centa in 19.8% of the cases. Abnormal placentation was
diagnosed post-delivery in 4.4% of the cases.
The study population comprised a total of 1064 cases
of severe PPH and 2059 random controls without severe
PPH. The distribution of potential risk factors is
presented in Table 2. Europe, the United States, and
Oceania were countries of origin for the majority of
cases and controls (78.8% vs. 81.7%, respectively). The
median (interquartile ranges) values for maternal age,
BMI, and birthweight were similar among cases and
controls; maternal age: 32 (29–36) years vs. 32 (29–35)
years respectively; pre-pregnancy BMI: 23.1 (21.0–26.1)
kg/m2 vs. 22.8 (20.8–25.7) kg/m2 respectively; and birth-
weight: 3546 (3075–3930) g vs. 3465 (3120–3834) g
respectively. In the univariable analysis, severe PPH was
more likely among women with the following medical
and obstetric characteristics: primiparity, women who
were married or cohabiting, previous severe PPH, previ-
ous uterine surgery, known uterine anomaly, multiple
gestation, IVF/ICSI pregnancies, anemia, gestational
diabetes mellitus, uterine fibroma, polyhydramnios,

















Birth canal trauma 114 (10.7%)
Surgical trauma during caesarean delivery 63 (5.9%)
Uterine rupture 12 (1.1%)
Thrombin 16 (1.5%)
Disseminated intravascular coagulation 8 (0.8%)
Pre-existing coagulation disorders 8 (0.8%)
Data presented as n (%)
a23% of the cases had two major causes listed
bexcluding cases with atony due to retained placental tissue
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Table 2 Clinical profile of women with severe postpartum hemorrhage versus controls
Severe PPH (N = 1064) Controls
(N = 2059)
OR 95% CI P -value
Age (years)
14 – 19 12 (1.1%) 13 (0.6%) 2.23 0.96 – 5.17 0.061
20 – 24 60 (5.6%) 145 (7.0%) Ref.
25 –29 240 (22.6%) 507 (24.6%) 1.14 0.82 – 1.60 0.435
30 –34 395 (37.1%) 770 (37.4%) 1.24 0.90 –1.71 0.194
35–39 283 (26.6%) 501 (24.3%) 1.36 0.98–1.91 0.068
≥40 74 (7.0%) 123 (6.0%) 1.45 0.96–2.21 0.078
Parity
0 622 (58.5%) 1007 (48.9%) 1.54 1.30 – 1.82 <0.001
1 296 (27.8%) 738 (35.8%) Ref.
2 96 (9.0%) 229 (11.1%) 1.04 0.79 – 1.37 0.752
≥3 50 (4.6%) 85 (4.1%) 1.47 1.01 – 2.13 0.045
Ethnicity
Europe/USA/Oceania 838 (78.8%) 1682 (81.7%) Ref.
Middle-East/North-Africa 50 (4.6%) 122 (5.9%) 0.82 0.58 – 1.15 0.259
Latin-America 14 (1.3%) 22 (1.1%) 1.28 0.65 – 2.51 0.477
Asia 99 (9.3%) 151 (7.3%) 1.31 1.01 – 1.72 0.044
Sub-Saharan Africa 63 (5.9%) 82 (4.0%) 1.54 1.10 – 2.16 0.012
BMI (kg/m2)
<18.5 42 (4.0%) 80 (3.9%) 1.08 0.74 – 1.59 0.688
18.5 – 24.9 639 (60.1%) 1317 (64.0%) Ref.
25.0 – 29.9 205 (19.3%) 378 (18.4%) 1.12 0.92 – 1.36 0.262
30.0 – 34.9 82 (7.7%) 145 (7.0%) 1.16 0.87 – 1.55 0.295
35.0 – 39.9 25 (2.4%) 36 (1.8%) 1.43 0.85 – 2.40 0.176
≥40 7 (0.7%) 14 (0.7%) 1.03 0.41 – 2.56 0.949
Married/cohabitant 973 (91.4%) 1932 (94.1%) 0.70 0.53 – 0.93 0.014
Pre-pregnancy conditions
Uterine anomaly 16 (1.5%) 13 (0.6%) 2.40 1.15 – 5.01 0.020
Uterine surgery 19 (1.8%) 11 (0.5%) 3.38 1.60 – 7.14 0.001
Previous cesarean 126 (11.8%) 221 (10.7%) 1.12 0.88 – 1.41 0.350
Previous severe PPH 66 (6.2%) 21 (1.0%) 6.42 3.90 – 10.6 <0.001
Obstetric factors
Multiple pregnancy 94 (8.8%) 52 (2.5%) 3.74 2.64 – 5.29 <0.001
IVF/ICSI 115 (10.8%) 82 (4.0%) 2.92 2.18 – 3.92 <0.001
Anemia (Hb ≤ 9.0 g/dL) 74 (7.0%) 38 (1.9%) 4.11 2.76 – 6.13 <0.001
Gestational diabetes mellitus 46 (9.4%) 58 (2.8%) 1.56 1.05 – 2.31 0.027
Uterine fibroma 52 (4.9%) 38 (1.9%) 2.73 1.79 – 4.18 <0.001
Polyhydramnios 16 (1.5%) 12 (0.6%) 2.60 1.23 – 5.52 0.013
Anticoagulant medication 51 (4.8%) 22 (2.1%) 4.66 2.81 – 7.73 <0.001
Severe pre-eclampsia or
HELLP syndrome
50 (4.7%) 28 (2.6%) 3.58 2.24 – 5.71 <0.001
Intrapartum factors
Mode of delivery
Spontaneous vaginal 507 (47.6%) 1358 (66.0%) Ref.
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receipt of anticoagulant medication, and severe pre-
eclampsia or HELLP syndrome. Severe PPH was more
likely among women with these intrapartum and deliv-
ery characteristics: instrumental vaginal delivery, in-
labor cesarean delivery, induced labor, labor augmenta-
tion with oxytocin, fever during labor, PROM, and infant
birth weight ≥4500 g.
Risk factors independently associated with severe PPH
are presented in Table 3. The strongest independent risk
factors were a history of severe PPH (adjusted odds ratio
(aOR) = 8.97; 95% CI: 5.25–15.33), anticoagulant drugs
in pregnancy (aOR = 4.78; 95% CI: 2.72–8.41), anemia
diagnosed in the start of pregnancy (aOR = 4.27; 95% CI:
2.79–6.54), severe pre-eclampsia or HELLP syndrome
(aOR = 3.03; 95% CI: 1.74–5.27), uterine fibromas
(OR = 2.71; 95% CI: 1.69–4.35), and multiple preg-
nancy (aOR = 2.11; 95% CI: 1.39–3.22). The H-L good-
ness-of-fit test was non-significant (chi-square = 12.99, P =
0.1122), indicating satisfactory model fit. The area under
the ROC curve was 0.7173, indicating an acceptable dis-
criminatory capability.
Finally, we performed an additional sensitivity analysis
where the outcome was limited to an estimated postpar-
tum blood loss ≥1500 mL. When considering the same
risk factors, the results of the sub-analysis did not
change our conclusions (Appendix: Table 4). Goodness-
of-fit of the model was indicated by a non-significant
H-L test (χ2 = 8.77, p = 0.3618), and a borderline discrim-
inatory capability (area under the ROC curve = 0.6927).
Discussion
In this case-control study, we evaluated risk factors for
severe PPH. A history of severe PPH was the strongest
independent risk factor in our study. Our findings sug-
gest that women with increased risk of severe PPH can
be identified when antepartum and intrapartum variables
are considered. Furthermore, retained placental tissue
was a much more frequent cause of severe PPH than
previously reported.
Strengths and limitations
The main strength of this case-control study was the
quality of the data source. By reviewing medical records,
we were able to evaluate potential risk factors for severe
PPH using a broad selection of clinical variables which
may not be easily retrieved from registries. In addition,
reading the medical records enabled us to present accur-
ate information on the causes of severe PPH and espe-
cially on the rate of retained placental tissue (including
abnormal placentation) in the cases. We lacked data on
women with suspected abnormal placentation prior to
delivery as there was little awareness around pre-
Table 2 Clinical profile of women with severe postpartum hemorrhage versus controls (Continued)
Instrumental vaginal 212 (20.0%) 25 (12.2%) 2.26 1.83 – 2.79 <0.001
In-labor cesarean 248 (23.3%) 245 (11.9%) 2.71 2.21 – 3.32 <0.001
Elective cesarean 97 (8.6%) 205 (10.0%) 1.27 0.97 – 1.65 0.077
PROM 127 (12.0%) 169 (8.2%) 1.51 1.19 – 1.93 0.001
Fever (temp > 38 °C) in labor 75 (7.1%) 60 (2.9%) 2.53 1.78 – 3.58 <0.001
Labor augmentation 587 (55.2%) 797 (38.7%) 1.95 1.68 – 2.26 <0.001
Labor induction 349 (32.8%) 402 (19.5%) 2.01 1.70 – 2.38 <0.001
Birth weight > 4500 g 51 (4.8%) 57 (2.8%) 1.77 1.20 – 2.60 0.004
Data presented as n (%), odds ratio (OR) and 95% confidence intervals (CI)
BMI body mass index, Hb hemoglobin, IVF/ICSI in vitro fertilization/intra-cytoplasmic sperm injection, HELLP hemolysis, elevated liver enzymes, low platelet count,
PROM premature rupture of membranes, PPH postpartum hemorrhage
Table 3 Multivariable logistic model for severe postpartum
hemorrhage
Independent risk factors Adjusted OR 95% CI P – value
Previous severe PPH 8.97 5.25 – 15.33 <0.001
Anticoagulant medication 4.79 2.72 – 8.41 <0.001
Anemia (Hb ≤ 9.0 g/dL) 4.27 2.79 – 6.54 <0.001
Severe preeclampsia or
HELLP syndrome
3.03 1.74 – 5.27 <0.001
Uterine fibromas 2.71 1.69 – 4.35 <0.001
Multiple pregnancy 2.11 1.39 – 3.22 <0.001
Mode of delivery
Spontaneous vaginal Ref.
Instrumental vaginal 1.50 1.17 – 1.93 0.001
In-labor cesarean 1.95 1.53 – 2.47 <0.001
Elective cesarean 1.66 1.22 – 2.24 0.006
IVF/ICSI 1.88 1.33 – 2.65 <0.001
Fever (>38 °C) 1.88 1.28-2.75 0.001
Labor induction 1.69 1.39 – 2.05 <0.001
Labor augmentation 1.59 1.32 – 1.91 <0.001
Birth weight > 4500 g 1.46 1.01 – 2.12 0.046
Primiparity 1.20 0.99 – 1.44 0.055
Area under ROC curve = 0.7173, Hosmer-Lemeshow χ2 = 12.99, p = 0.1122
PPH postpartum hemorrhage, Hb hemoglobin, HELLP hemolysis, elevated liver
enzymes, low platelet count, IVF/ICSI in vitro fertilization/intra-cytoplasmic
sperm injection
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delivery diagnosis of abnormal placentation in Norway
during the study period. Abnormal placentation could
therefore not be included as a risk factor for severe PPH
in our model.
Assessing risk factors in retrospect is a limitation in
this study. In order to minimize selection bias, we
selected all cases of severe PPH and a random sample of
controls from the same source population. There is a
possibility that some cases were misclassified. Blood loss
was estimated visually in the three hospitals included in
our study, and the blood loss may have been underesti-
mated [23, 24]. However, we had further data in medical
records to assess the severity of the hemorrhage by need
for blood transfusion. There is a possibility of informa-
tion bias due to misclassification of the exposures. How-
ever, neither the resident obstetrician nor midwife were
aware of our research questions, therefore the potential
for misclassification of risk factors would be non-
differential creating a bias toward the null [20]. The
sample size provided adequate power to highlight risk
factors mildly associated with severe PPH, such as infant
birth weight. However, we did not account for multiple
testing in the power analysis and the smallest detectable
odds ratios may have been underestimated.
We based our results on deliveries in three hospitals in or
close to Oslo, Norway, and our results may not necessarily
be generalizable to other delivery populations in well-
resourced countries. The majority of the women in this
study had European, USA, or Oceanian ethnicity, and was
non-obese and married. These characteristics reflect a
society with a low proportion of women with low socioeco-
nomic status and fewer immigrants compared to other
well-resourced countries. Furthermore, the hospitals mainly
reflect an urban setting, but urban-rural differences in
Norway are small and home births are an exception.
Important risk factors for severe PPH
The strongest risk factor in our study was a history of
severe PPH. Women with a history of severe PPH had
nine-fold increased odds of severe PPH in their index
pregnancy. Previously reported estimates on recurrence
risk are mainly from register-based studies [25–27],
presenting lower estimates between 2.2 and 3.3. Having
a history of PPH may be less well-reported to the regis-
tries than in our data sources. Likewise, a validation
study from Australia [28] reported a recurrence rate of
28% from medical record audits, while the reported re-
currence rate in register based data was 18%. The causes
of PPH recurrence were investigated in a population
study from Sweden [27]. They reported that recurrence
risk could not be explained by known risk factors for
PPH, suggesting that recurrence may depend on
environmental and genetic factors. Another study by the
same authors [29] reported that, among vaginal deliveries,
18% of the variation in PPH liability may be explained by
maternal genetic factors. Alterations in maternal
hemostasis and oxytocin signaling at the myometrial level
were postulated as possible pathways for a maternal
genetic predisposition to PPH.
A close to five-fold increased risk of severe PPH was
found in women using anticoagulant drugs in pregnancy.
The obstetric guidelines in Norway recommend stopping
anticoagulants at the onset of labor or 12 h before a
planned cesarean delivery. Our finding is in line those
from a Swedish study [30]. In this study, the risk of PPH
was increased three-fold for women using anticoagulants
in pregnancy. Other studies, however, have not found
any significantly increased risk of severe PPH associated
with the use of anticoagulant drugs [31, 32]. Differences
in anticoagulant drug regimens may explain why this
association has not been consistently shown across these
studies. Of note, in our analyses, we did not account for
drug dosing or the time interval between last anticoagu-
lant dose and PPH onset.
Obstetric interventions, such as augmentation and
induction of labor, instrumental vaginal delivery, and
cesarean delivery, were all significantly associated with
severe PPH. A potential for risk reduction is likely if the
use of these interventions are limited to situations where
existing evidence supports their safe use. In line with
previous studies, compared with spontaneous vaginal
delivery, the odds of severe PPH were higher among
women undergoing either in-labor or planned cesarean
delivery [1, 33]. Previous studies have shown conflicting
results [1, 34–36] on whether labor augmentation is a
risk factor independent of induction. Oxytocin receptor
desensitization may explain why labor augmentation
with oxytocin is associated with uterine atony leading to
PPH [37–39]. The association between oxytocin admin-
istration and PPH has been reported to be dose related
and evidence-based guidelines are needed to determine
optimal oxytocin regimens for labor augmentation to
lessen the risk of atonic PPH [34].
We found that an IVF or ICSI pregnancy was an inde-
pendent risk factor for severe PPH. This association has
been poorly described, and previous studies observing an
association between assisted reproductive technology and
severe PPH are from retrospective infertility cohorts
[40–42]. Events around the implantation of the placenta,
such as low placement of the embryo into the uterus and
endometrial function disturbances, could play a role here.
As the use of assisted reproductive technology is increas-
ing, more research to investigate the potential association
between IVF and ICSI pregnancies and PPH is warranted.
Frequency and causes of severe PPH
In our study, the frequency of severe PPH was 2.5%. A
population-based study from Norway using the Norwegian
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Birth Registry [18], reported a severe PPH rate of 1.1%. The
difference can be explained by a tendency to underreport
cases of severe PPH to the birth registries. A validation
study from Australia [43] showed an underreporting of
obstetric hemorrhage with a sensitivity of only 74% in
population-based registry studies.
In a study examining risk factors and outcomes of
massive blood transfusions during delivery [44], abnormal
placentation was reported to be the most common cause
(26.6%). The same study reported that a disproportionate
number of women who received a massive blood transfu-
sion experienced severe maternal morbidity, illustrating
why abnormal placentation is becoming a major concern in
obstetrics. In our study, we identified placental problems
(retained placenta, retained placental tissue and abnormal
placentation) as the cause of severe PPH in nearly 36% of
cases. Abnormal placentation was diagnosed post-delivery
in 4.4% of cases. In addition, abnormal placentation may
have been present for some cases diagnosed as retained
placenta as pathology reports are not available for the
majority of these cases. Retained placental tissue, including
abnormal placentation, has been estimated to cause
approximately 10% of all PPHs [8, 24]. Our findings suggest
that retained placental tissue may be a more prominent
cause of severe PPH than previously reported. False report-
ing of cases caused by retained placental tissue as atonic
bleeding in registries could explain this discrepancy. In a
validation study examining the contribution of uterine
atony to PPH [28], the incidence of uterine atony was over-
estimated by 10% when registry data were compared with
clinical data. Access to detailed medical information en-
abled us to accurately estimate the proportion of cases with
placental problems in our population. We believe the high
rate of placental problems revealed in the current study
could reflect an increasing rate of placental problems.
Conclusion
In this study, the strongest risk factors for severe PPH
was a history of severe PPH, anticoagulant medication,
anemia, severe preeclampsia or HELLP syndrome,
uterine fibromas, and multiple pregnancy. Including these
risk factors in clinical guidelines could help to identify
women with high risk of severe PPH prior to delivery. By
identifying these women, adequate resources and staff
could be mobilized in preparation for severe bleeding at
the time of delivery. Several of the identified risk factors in
our study were related to medical and obstetric interven-
tions such as anticoagulant medication, assisted reproduct-
ive technologies, labor induction, and labor augmentation
with oxytocin. Further studies are needed to better under-
stand the risk-benefit profile of each intervention on
maternal outcomes. Risk factors identified in our study
could be considered in future studies examining risk
prediction models for severe PPH.
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